?Vonoprazan Fumarate Intermediate (CAS 1240948-77-9)?
Google Keywords: Vonoprazan Intermediate, CAS 1240948-77-9, Gastrointestinal Drug Synthesis, P-CAB API Manufacturing, GMP Pharmaceutical Intermediates

?? ?Product Overview?

?Vonoprazan Fumarate Intermediate? (CAS 1240948-77-9) is a critical high-purity chemical intermediate used in synthesizing ?Vonoprazan Fumarate?, a potassium-competitive acid blocker (P-CAB) approved for treating acid-related gastrointestinal disorders, including gastric ulcers and reflux esophagitis. This intermediate ensures precise and scalable production of the API, aligning with global pharmaceutical quality standards.

• ?Primary Function?: Key building block for Vonoprazan Fumarate API synthesis, enabling robust and selective chemical transformations.

• ?Applications?: Gastrointestinal drug development, acid suppression therapies, and large-scale API manufacturing.

? ?Key Advantages?

?? ?Ultra-High Purity? | ≥99.5% (HPLC/GC verified) | Complies with ICH Q11 guidelines for pharmaceutical intermediates.
?? ?Scalable Process? | Optimized for high-yield synthesis (>85% efficiency) with minimal byproducts, reducing production costs.
?? ?Regulatory Ready? | Fully characterized (NMR, HRMS, FTIR) to support FDA/EMA filings and GMP compliance.

?? ?Applications?

1. ?API Manufacturing?: Enables efficient synthesis of Vonoprazan Fumarate with consistent batch-to-batch quality.

2. ?Process Development?: Accelerates R&D for optimizing synthetic routes and enhancing production sustainability.

3. ?Quality Assurance?: Used in analytical method validation and stability testing during API release.

?? ?Quality Assurance?

• ?Testing Methods?: HPLC, GC, NMR, HRMS, and FTIR for structural verification and impurity profiling.

• ?Standards?: Meets USP <1086>, EP 10.0, and ISO 9001:2015 certified production protocols.

?? ?Market Trends?

The ?global acid-related disorder treatment market? is projected to reach ?$6.8 billion by 2030? (CAGR 4.9%), driven by rising prevalence of GERD and demand for fast-acting therapies like Vonoprazan. This intermediate supports rapid scaling of P-CAB drug production to meet global healthcare needs.

Power your gastrointestinal drug pipeline with Vonoprazan Fumarate Intermediate – precision-engineered for purity, scalability, and compliance.